Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BPH Global's gross profit for the
six
months ended in Dec. 2025 was A$-0.06 Mil. BPH Global's gross profit for the trailing twelve months (TTM) ended in Dec. 2025 was A$-0.05 Mil.
Gross Margin % is calculated as gross profit divided by its revenue. BPH Global's gross profit for the
six
months ended in Dec. 2025 was A$-0.06 Mil. BPH Global's Revenue for the
six
months ended in Dec. 2025 was A$1.38 Mil. Therefore, BPH Global's Gross Margin % for the quarter that ended in Dec. 2025 was -4.36%.
BPH Global had a gross margin of -4.36% for the quarter that ended in Dec. 2025 => No sustainable competitive advantage
During the past 13 years, the highestGross Margin % of BPH Global was 22.68%. The lowest was -16.00%. And the median was 15.93%.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
BPH Global had a gross margin of -4.36% for the quarter that ended in Dec. 2025 => No sustainable competitive advantage
BPH Global Gross Profit Related Terms
BPH Global Gross Profit Historical Data
* Premium members only.
The historical data trend for BPH Global's Gross Profit can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, BPH Global's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BPH Global Gross Profit vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, BPH Global's Gross Profit distribution charts can be found below:
* The bar in red indicates where BPH Global's Gross Profit falls into.
Gross Profit for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$-0.05 Mil.
Gross Profit is the numerator in the calculation of Gross Margin.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
BPH Global (ASX:BP8) has a Gross Profit of A$-0.05 Mil as of Dec. 2025. Gross Profit equals net sales less total cost of goods sold. View historical data on BPH Global and its competitors.
Is BPH Global's Gross Profit too high?
BPH Global's current Gross Profit is A$-0.05 Mil.
How does BPH Global's Gross Profit compare to ZTS?
BPH Global's Gross Profit of A$-0.05 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Profit for a Drug Manufacturers company?
A good Gross Profit depends on the Drug Manufacturers industry context. However, Gross Profit should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Profit mean?
A high Gross Profit can signal that a stock is expensive relative to its fundamentals. Gross Profit equals net sales less total cost of goods sold. View historical data on BPH Global and its competitors. BPH Global's current Gross Profit is A$-0.05 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BPH Global stock overvalued right now?
BPH Global (ASX:BP8) has a current Gross Profit of A$-0.05 Mil. The current Gross Profit is A$-0.05 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Profit calculated?
Gross Profit is calculated from a company's financial statements. For BPH Global (ASX:BP8), the current Gross Profit is A$-0.05 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
BPH Global Ltd is a plant-focused biotechnology company with a focus on producing foods, health, and cosmetic products that deliver Traditional Chinese Medicine (TCM)-based health outcomes. It focuses on the research, development, production, and commercialization of TCM products, including bird's nest, seaweeds, and sea plants, which serve as sustainable plant-based protein sources and ingredients for food, nutrition, healthcare, cosmetics, and personal care industries. The company's geographical segment includes Australia, Indonesia, and China. The company's products comprise raw and processed bird's nest, sea grapes (Caulerpa lentillifera), and other seaweeds and sea plants.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:BP8 has been successfully added to your 
